NO20042993L - Formulering og doseringsform for kontrollert levering av terapeutiske midler - Google Patents

Formulering og doseringsform for kontrollert levering av terapeutiske midler

Info

Publication number
NO20042993L
NO20042993L NO20042993A NO20042993A NO20042993L NO 20042993 L NO20042993 L NO 20042993L NO 20042993 A NO20042993 A NO 20042993A NO 20042993 A NO20042993 A NO 20042993A NO 20042993 L NO20042993 L NO 20042993L
Authority
NO
Norway
Prior art keywords
formulation
dosage form
therapeutic agents
controlled delivery
delivery
Prior art date
Application number
NO20042993A
Other languages
English (en)
Inventor
Patrick S L Wong
Steven D Espinal
Liang-Chang Dong
Vu A Nguyen
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20042993L publication Critical patent/NO20042993L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
NO20042993A 2001-12-19 2004-07-13 Formulering og doseringsform for kontrollert levering av terapeutiske midler NO20042993L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34300101P 2001-12-19 2001-12-19
PCT/US2002/040763 WO2003053400A1 (en) 2001-12-19 2002-12-19 Formulation & dosage form for the controlled delivery of therapeutic agents

Publications (1)

Publication Number Publication Date
NO20042993L true NO20042993L (no) 2004-09-20

Family

ID=23344252

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042993A NO20042993L (no) 2001-12-19 2004-07-13 Formulering og doseringsform for kontrollert levering av terapeutiske midler

Country Status (14)

Country Link
US (1) US20030232078A1 (no)
EP (1) EP1458353A1 (no)
JP (1) JP2005513095A (no)
KR (1) KR20040090961A (no)
CN (1) CN1620281A (no)
AU (1) AU2002357930B2 (no)
CA (1) CA2471081A1 (no)
HU (1) HUP0402661A3 (no)
IL (1) IL162294A0 (no)
MX (1) MXPA04006025A (no)
NO (1) NO20042993L (no)
NZ (1) NZ533062A (no)
WO (1) WO2003053400A1 (no)
ZA (1) ZA200405657B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
WO2003070273A1 (en) * 2002-02-25 2003-08-28 Lyfjathroun Hf A bioadhesive agent
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
KR20050071376A (ko) * 2002-06-28 2005-07-07 알자 코포레이션 액체 활성성분 제제를 포함하고 팽창성 삼투 조성물에의해 그의 방출을 제어하는 경구제형
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
JP2006507309A (ja) * 2002-10-31 2006-03-02 アルザ・コーポレーシヨン 疎水性薬剤の上昇した生物学的利用性を提供する製剤
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0308732D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
GB0308734D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
AU2004261277A1 (en) * 2003-07-31 2005-02-10 Alza Corporation Permeation-Resistant osmotic engine and dosage form for controlled release of a liquid active agent formulation
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US20050070608A1 (en) * 2003-08-29 2005-03-31 Julius Remenar Pharmaceutical compositions and method of using levodopa and carbidopa
EP1667652B1 (en) * 2003-09-26 2007-05-30 ALZA Corporation Improved controlled release dosage form including a banded engine
US20050112190A1 (en) * 2003-09-26 2005-05-26 Wiser Lauren M. Dosage form for controlled release of an active agent formulation
JP4919801B2 (ja) 2003-09-26 2012-04-18 アルザ・コーポレーシヨン 高い薬剤配合量を提供する薬剤コーティング及びそれを提供する方法
NZ546183A (en) * 2003-09-26 2011-04-29 Alza Corp Controlled release formulations exhibiting an ascending rate of release
AU2004285533A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8707964B2 (en) 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8303573B2 (en) 2007-10-17 2012-11-06 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808276B2 (en) 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
US8808271B2 (en) 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8109920B2 (en) * 2007-10-31 2012-02-07 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8333754B2 (en) 2007-10-31 2012-12-18 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CA2735889A1 (en) * 2008-09-10 2010-03-18 Silipos, Inc. Gelatinous elastomer compositions
CA2747998C (en) 2008-12-22 2016-05-31 Allergan, Inc. Safe desmopressin administration
KR101792696B1 (ko) 2009-06-18 2017-11-02 알레간 인코포레이티드 안전한 데스모프레신 투여
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9622981B2 (en) 2011-11-17 2017-04-18 Mylan Inc. Liquid-filled hard gel capsule pharmaceutical formulations
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (no) * 1960-11-29
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) * 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3865108A (en) * 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) * 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4207893A (en) * 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5178866A (en) * 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5234280B2 (en) * 1992-03-30 1997-12-09 Plastic Safety Systems Inc Traffic channeling devices
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5637319A (en) * 1995-03-01 1997-06-10 Takada; Kanji Controlled-release preparations
US5998598A (en) * 1997-03-10 1999-12-07 The United States Of America, As Represented By The Department Of Health And Human Services Immunoadhesins and methods of production and use thereof
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
PT1140012E (pt) * 1998-12-17 2004-05-31 Alza Corp Conversao de capsulas de gelatina cheias com liquido em sistemas de libertacao controlada por camadas multiplas
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin

Also Published As

Publication number Publication date
IL162294A0 (en) 2005-11-20
MXPA04006025A (es) 2005-03-31
KR20040090961A (ko) 2004-10-27
ZA200405657B (en) 2005-08-29
US20030232078A1 (en) 2003-12-18
AU2002357930B2 (en) 2007-06-28
HUP0402661A3 (en) 2008-04-28
NZ533062A (en) 2006-03-31
EP1458353A1 (en) 2004-09-22
CA2471081A1 (en) 2003-07-03
AU2002357930A1 (en) 2003-07-09
WO2003053400A1 (en) 2003-07-03
CN1620281A (zh) 2005-05-25
JP2005513095A (ja) 2005-05-12
HUP0402661A2 (hu) 2005-07-28

Similar Documents

Publication Publication Date Title
NO20042993L (no) Formulering og doseringsform for kontrollert levering av terapeutiske midler
DE60121992D1 (de) Zusammensetzung zur verabreichung und beschichtung medizinischer geräte
IS6892A (is) Lyfjasamsetningar, skammtaform og aðferðir til aðgefa epóþílon um munn
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
AU2003297621A8 (en) Medical devices for delivery of therapeutic agents
EP1416884A4 (en) DISTRIBUTION OF AGENTS WITH THERAPEUTIC PROPERTIES
NO20050956L (no) Fremgangsmate og doseringsformer for kontrollert levering av paliperidon
HUP0301121A3 (en) Topical pharmaceutical formulations and methods of treatment
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
TWI346558B (en) Pharmaceutical composition for chronic treatment of inflammation and use thereof
IS7076A (is) Bólusetning með einföldum skammti af Mycoplasma hyopneumoniae, og notkun efnisins í lækningaskyni
IL160419A0 (en) Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
NO20035438L (no) Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
BRPI0209720A2 (pt) dosagem e embalagem de medicação com liberação controlada
NO20042208L (no) Vaginalt administrerte anti-dysrytmiske midler for behandling av bekkensmerter
NO20034709D0 (no) Fremgangsmåte for fremstilling av lav dose farmasöytisk sammensetning med jevn medikament fordeling og potens
HUP0304045A3 (en) Use of ikb-kinase inhibitors for treating of inflammatory and immune diseases and pharmaceutical compositions containing them
EE200300501A (et) Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid
NO20040047L (no) Farmasoytisk formulering for intramuskulaer administrering av fulvestrant
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
IS6532A (is) Lyfjaform til stýrðrar losunar á síprófloxasíni með inntöku um munn einu sinni á dag
NO20030794D0 (no) Fremgangsmåter for legemiddelavlevering til hepatocytter og behandling av flavivirida-infeksjoner
DE60142584D1 (de) Multilumen katheter und implantate zur verabreichung von therapeutischen substanzen an gewebe
HUP0302535A3 (en) Peptide compounds, pharmaceutical compositions containing them and their use for treatment of no-mediated diseases
DK1372665T3 (da) Hormonerstatningsbehandling og administration

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application